secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2026-05-21T20:23:32+00:00
Accession:  0001437749-26-018098
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical publishes clinical data showing 81.8% cellulite improvement with Avéli-Renuvion combination
--------------------------------------------------------------------------------

- 22 patients received single-session treatment combining Avéli subcision and Renuvion helium plasma RF.
- Up to 81.8% of patients showed improvement in cellulite appearance at 180 days post-treatment.
- 3D imaging confirmed measurable reductions in dimple volume, surface area, and depth.
- Histological analysis in a subset showed increased collagen and elastin with progressive tissue remodeling.
- Study published in Aesthetic Surgery Journal Open Forum; supports combined approach for cellulite and skin laxity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774926018098/0001437749-26-018098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774926018098/apyx20260521_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-018098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer